Table 4. Univariate analysis of disease-free and overall survival rate.

		Disease-free survival			Overall survival
Variable	N	HR	95% CI	P	HR	95% CI	P
Sex
Female	25	1			1
Male	127	1.021	0.546–1.909	0.946	1.670	0.588–4.745	0.336
Age (years)
<50	43	1			1
≥50	109	1.395	0.791–2.461	0.249	1.344	0.604–2.992	0.469
Etiology
Viral (HBV, HCV)	121	1			1
Non-viral	31	1.371	0.790–2.381	0.261	1.307	0.611–2.798	0.490
Tumor size
<4 cm	83	1			1
≥4 cm	69	1.974	1.213–3.211	0.006	6.925	2.859–16.769	<0.001
Multiplicity
Single	134	1.000			1
Multiple	18	1.437	0.731–2.824	0.292	1.251	0.381–4.101	0.712
Differentiation
Well/moderate	124	1			1
Poor	28	1.554	0.885–2.726	0.124	1.836	0.867–3.887	0.112
Preoperative treatment
No	101	1			1
Yes	51	2.307	1.422–3.744	<0.001	0.978	0.476–2.009	0.951
Vascular invasion
Absence	63	1			1
Presence	89	2.841	1.636–4.935	<0.001	14.769	3.534–61.715	<0.001
Intrahepatic metastasis
Absence	136	1			1
Presence	16	3.298	1.712–6.350	<0.001	4.563	2.035–10.232	<0.001
Histologic group
EpCAM(−)/K19(−) HCCs	61	1		0.004	1		0.002
EpCAM(+)/K19(+) HCCs	35	2.148	1.092–4.226	0.026	16.533	2.091–130.707	0.008
cHC-CCs	56	2.812	1.530–5.167	0.001	29.442	3.953–219.286	0.001
YAP1 expression *
Negative	85	1			1
Positive	67	1.261	0.777–2.046	0.346	1.990	0.988–4.008	0.050

^*Nuclear YAP1 expression with moderate to strong intensities in more than 5% of the tumor cells were regarded as positive.